Bristol-Myers Squibb, a company known for its cancer immunotherapy drugs, just acquired immunotherapy startup IFM Therapeutics.
ADVERTISEMENT
Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy (BMY)
IFM has two preclinical programs, which work to enhance the immune system's response to cancer cells.
cancer cells
ADVERTISEMENT
Recommended articles
The deal is worth $300 million upfront, and if IFM's two drug programs hit certain development milestones, Bristol-Myers could pay an additional $1.01 billion for each, adding up to a total of $2.32 billion.
IFM has two preclinical programs, which work to enhance the immune system's response to cancer cells.
Bristol-Myers has two drugs, Opdivo and Yervoy, that are a part of a new class of cancer treatments called cancer immunotherapy that harness the body's immune system to go after cancer. chemotherapy
ADVERTISEMENT
The drugmaker has made other immunotherapy deals in the past. In March, it partnered with CytomX in a deal that could be worth $3.8 billion. CytomX is trying to do is activate the drug only when it's by diseased tissue, using something called "Probodies." That way, it might be possible to reduce some of the side effects that current cancer immunotherapy treatments have.
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
10 African countries with the most intelligent people - report
5 interesting facts about Nigeria’s second richest man as he marks 71 years
Ireland considers halting visa-free travel for South Africa
The US asserts that it is a better option for Africa than Russia and China
Malak El Masry speaks on championing entrepreneurship and art in Africa
Junta led Burkina Faso suspends more foreign media over killings coverage
10 African countries with the strongest merchant marine fleet
Who are Africa's biggest Esports teams?
